Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved crawled time : 11:00 save search
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Published: 2024-04-24 (Crawled : 11:00) - globenewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: -2.2%
H: 0.0%
C: -5.71%
filspari nephropathy treatment for therapeutics
Science Based Targets initiative Approves Otis Targets for Reducing Greenhouse Gas Emissions
Published: 2024-04-22 (Crawled : 11:00) - prnewswire.com
OTIS | News | $93.37 -4.21% 1.74% 4.2M
|
Producer Manufacturing
|
| O: -0.22%
H: 1.51%
C: 0.9%
initiative gas for
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
OCGN | News 4 | $1.18 -5.6% -6.84% 7.2M
|
Health Technology
|
| O: 2.92%
H: 3.41%
C: 2.27%
ocu400 approval positive for therapy
Gogo Secures FCC Regulatory Approval for Gogo Galileo Terminals
Published: 2024-04-09 (Crawled : 11:00) - prnewswire.com
GOGO | $8.73 1.63% 1.49% 660K
|
Communications
|
| O: 1.81%
H: 8.04%
C: 3.43%
approval for
3M Settlement with Public Water Suppliers to Address PFAS in Drinking Water Receives Final Court Approval
Published: 2024-04-01 (Crawled : 11:00) - prnewswire.com
MMM | $92.02 -1.05% 0.17% 2.7M
|
Producer Manufacturing
|
| O: -13.06%
H: 3.61%
C: 3.26%
water approval
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Adults
Published: 2024-03-28 (Crawled : 11:00) - biospace.com/
MRK | $127.0 0.1% 0.63% 5.7M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
keytruda lung cancer cell risk plus
EBRD and Erste Approve Financing for the Pupin Windfarm in Serbia
Published: 2024-03-27 (Crawled : 11:00) - globenewswire.com
ENLT | $16.03 -2.61% -2.68% 16K
|
n/a
|
| O: 0.18%
H: 1.52%
C: 0.93%
ATHA Energy Announces 92 Energy Obtains Court Approval
Published: 2024-03-27 (Crawled : 11:00) - globenewswire.com
NXE | $7.81 -0.13% 2.18% 2.1M
|
Non-Energy Minerals
|
| O: 0.13%
H: 1.18%
C: 1.18%
energy approval
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
Published: 2024-03-21 (Crawled : 11:00) - globenewswire.com
TELA | $4.47 0.0% 85K
|
Health Technology
|
| O: -0.91%
H: 9.52%
C: -2.01%
commercial
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
Published: 2024-03-20 (Crawled : 11:00) - globenewswire.com
ORTX | $16.7 0.0% 370K
|
Health Technology
| Email alert
Add to watchlist
children approved therapeutics therapy
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
Published: 2024-03-19 (Crawled : 11:00) - prnewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: -0.7%
H: 5.47%
C: 4.91%
ferinject health anemia approved treatment canada heart
Tilray Medical Receives Approval for First Medical Cannabis Extract in Portugal
Published: 2024-03-14 (Crawled : 11:00) - globenewswire.com
TLRY | $1.83 -0.54% -0.55% 18M
|
Process Industries
|
| O: 0.0%
H: 0.6%
C: -4.19%
first cannabis approval medical tilray
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
Published: 2024-03-14 (Crawled : 11:00) - biospace.com/
BSX | $72.91 5.68% -0.01% 13M
|
Health Technology
|
| O: -0.15%
H: 1.47%
C: 1.4%
AXNX | $66.64 0.26% 0.3% 400K
|
Health Technology
|
| O: -0.06%
H: 0.35%
C: 0.07%
axonics approval system
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
Published: 2024-03-13 (Crawled : 11:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% 0.19% 18M
|
Health Technology
|
| O: 1.0%
H: 1.41%
C: -0.25%
disease pneumococcal children
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
Published: 2024-03-12 (Crawled : 11:00) - globenewswire.com
BCDA P | $0.3795 0.93% -2.56% 73K
|
Health Technology
|
| O: 5.58%
H: 2.85%
C: -14.27%
approval cell cardiamp heart therapy study
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: -0.81%
H: 1.51%
C: -6.98%
filspari nephropathy drug approval food treatment application therapeutics
Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
PLUR | $5.09 1.8% 0.2% 12K
|
Manufacturing
|
| O: 0.0%
H: 0.99%
C: -4.1%
patent approval cell technology
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
ADMA 4 | $6.46 -1.22% -1.16% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -2.52%
bivigam fda
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: 0.23%
H: 0.9%
C: -0.68%
praluent fda children genetic cholesterol approval treat injection
Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries
Published: 2024-02-27 (Crawled : 11:00) - globenewswire.com
GLSI | $12.62 -3.96% -4.29% 29K
|
Health Technology
|
| O: 8.53%
H: 0.0%
C: -4.65%
approved lifesciences trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
RILY | $29.75 36.97% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.